Danaher Co. (NYSE:DHR) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. lessened its stake in shares of Danaher Co. (NYSE:DHR) by 64.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 34,179 shares of the conglomerate’s stock after selling 61,689 shares during the quarter. Connor Clark & Lunn Investment Management Ltd.’s holdings in Danaher were worth $7,846,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Rakuten Securities Inc. grew its holdings in shares of Danaher by 380.0% during the fourth quarter. Rakuten Securities Inc. now owns 168 shares of the conglomerate’s stock worth $39,000 after purchasing an additional 133 shares during the last quarter. Avantax Advisory Services Inc. grew its stake in Danaher by 2.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 38,108 shares of the conglomerate’s stock worth $8,748,000 after buying an additional 1,079 shares during the last quarter. Hopwood Financial Services Inc. acquired a new position in Danaher during the fourth quarter worth approximately $69,000. Farther Finance Advisors LLC lifted its stake in Danaher by 13.8% in the fourth quarter. Farther Finance Advisors LLC now owns 7,784 shares of the conglomerate’s stock valued at $1,787,000 after buying an additional 943 shares during the last quarter. Finally, Knuff & Co LLC boosted its holdings in shares of Danaher by 1.8% in the fourth quarter. Knuff & Co LLC now owns 8,407 shares of the conglomerate’s stock valued at $1,930,000 after acquiring an additional 149 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Up 3.4 %

Shares of DHR stock opened at $211.09 on Friday. The stock has a market cap of $150.87 billion, a P/E ratio of 39.98, a P/E/G ratio of 2.66 and a beta of 0.82. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The business has a fifty day simple moving average of $220.07 and a 200-day simple moving average of $240.63.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the company earned $2.09 earnings per share. On average, analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.61%. This is a boost from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. Danaher’s payout ratio is 24.24%.

Analyst Upgrades and Downgrades

Several research firms recently commented on DHR. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price target for the company in a research report on Friday, December 13th. Guggenheim initiated coverage on shares of Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and set a $277.00 price target (down previously from $299.00) on shares of Danaher in a report on Thursday, January 30th. Citigroup reduced their price objective on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Finally, Raymond James reiterated a “market perform” rating on shares of Danaher in a research note on Monday, February 3rd. Six research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $277.76.

Insider Activity

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.